For example, the entry inhibitor enfuvirtide is generally active in heavily treatment-experienced patients, but must be injected subcutaneously twice a day. These drug traits exacerbate ...

There is strong evidence that PRM-A is a viral entry inhibitor; in other words, it stops viruses from entering a host's cells. It does this by binding to N-glycans, which are found on the surface ...

HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry ...

Inhibitors of virus entry can prevent virus attachment, or bind to entry intermediates; small organic molecules, peptides, soluble receptors and antibodies are in clinical trials. Six virus ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in PTPN2.